GlobeNewswire Inc.··NaGalapagos and Gilead Team Up on Breakthrough T Cell Engager for Autoimmune Diseases
Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.
GILDGLPGautoimmune diseasesorphan drug designation